BetaVolt's BV100 is smaller than a coin and contains a radioactive isotope of nickel that decays into copper and supplies power to a device for up to 50 years. But it probably won't power your ...

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by ...

BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027 ...

Biopharmaceutical company BioVersys has announced the grant of key patent claims in China for BV100, the intravenous formulation of rifabutin. The technology is being developed to combat resistant ...

In addition to BV100, BioVersys is advancing other pipeline assets. The company established a global research collaboration with Shionogi for BV500, targeting non-tuberculous mycobacteria infections.

China's Betavolt New Energy Technology has unveiled a new modular nuclear battery that uses a combination of a nickel-63 (⁶³Ni) radioactive isotope and a 4th-generation diamond semiconductor and can ...

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by ...

Panel of independent experts selected BioVersys' BV100 out of 24 candidates to participate in the ADVANCE-ID and National University of Singapore (NUS) Asia clinical trial network of 130 sites across ...

BioVersys AG, a multi-asset, late-stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug ...

Important patent around BioVersys’ BV100 drug candidate has been granted, protecting the proprietary rifabutin IV formulation technology in China BV100 patents have now been granted in over 25 ...